Ikena Oncology, Inc. (NASDAQ:IKNA) is BML Capital Management LLC’s 10th Largest Position

BML Capital Management LLC lifted its holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) by 395.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,585,866 shares of the company’s stock after purchasing an additional 2,862,578 shares during the quarter. Ikena Oncology accounts for about 3.7% of BML Capital Management LLC’s investment portfolio, making the stock its 10th biggest holding. BML Capital Management LLC owned 0.07% of Ikena Oncology worth $5,881,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of IKNA. Peapod Lane Capital LLC purchased a new position in shares of Ikena Oncology in the fourth quarter worth $833,000. BBR Partners LLC increased its position in Ikena Oncology by 550.0% during the third quarter. BBR Partners LLC now owns 130,000 shares of the company’s stock valued at $225,000 after acquiring an additional 110,000 shares during the last quarter. NEA Management Company LLC increased its position in Ikena Oncology by 5.3% during the third quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock valued at $1,038,000 after acquiring an additional 30,013 shares during the last quarter. FMR LLC increased its position in Ikena Oncology by 94.1% during the third quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after acquiring an additional 18,607 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Ikena Oncology by 5.6% during the third quarter. Geode Capital Management LLC now owns 271,026 shares of the company’s stock valued at $469,000 after acquiring an additional 14,319 shares during the last quarter. Hedge funds and other institutional investors own 75.00% of the company’s stock.

Ikena Oncology Stock Performance

NASDAQ:IKNA opened at $1.43 on Friday. The stock has a 50-day simple moving average of $1.49 and a two-hundred day simple moving average of $1.62. Ikena Oncology, Inc. has a 52-week low of $1.22 and a 52-week high of $1.94. The firm has a market capitalization of $69.01 million, a PE ratio of -1.16 and a beta of 0.49.

Ikena Oncology (NASDAQ:IKNA) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. Equities analysts forecast that Ikena Oncology, Inc. will post -0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on IKNA shares. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Ikena Oncology in a research report on Monday, November 11th. Wedbush reiterated a “neutral” rating and set a $2.00 price objective on shares of Ikena Oncology in a research report on Monday, December 23rd.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.